Julie Nagpal1, Lourdes Oriana Linares2, Jocelyn Weiss2, Nicolas F Schlecht3, Viswanathan Shankar4, Debra Braun-Courville2, Anne Nucci-Sack2, Howard D Strickler4, Robert D Burk4, Angela Diaz2. 1. Department of Pediatrics, The Mount Sinai Medical Center, New York, NY. Electronic address: julie.nagpal@nychhc.org. 2. Department of Pediatrics, The Mount Sinai Medical Center, New York, NY. 3. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY; Departments of Pediatrics, Microbiology & Immunology, and Obstetrics & Gynecology and Women's Health, Albert Einstein College of Medicine, Bronx, NY. 4. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY.
Abstract
OBJECTIVE: To examine the association of knowledge about human papillomavirus (HPV) on the time to completion of the 3-dose quadrivalent vaccine series in an inner-city population of adolescent female subjects at high risk for infection. STUDY DESIGN: We prospectively followed 139 female subjects aged 14-20 years enrolled in a vaccine surveillance study in New York City during a period of at least 24 months. Participants were given a 30-item true or false survey on HPV at enrollment and ranked according to the number of correct responses. Multivariate Cox regression was used to examine the association between level of knowledge about HPV and time to completion (in days) of vaccine dose 1-3, dose 1-2, and dose 2-3. RESULTS: Overall time to completion of the 3-dose vaccine ranged from 158 days to 1114 days. Participants in the high knowledge group (top quartile) were significantly more likely to complete the 3-dose series earlier (hazard ratio 1.69, 95% CI 1.03-2.77; P = .04), in particular doses 2-3 (hazard ratio 1.71, 95% CI 1.02-2.89; P = .04), than those with low-to-moderate knowledge (bottom 3 quartiles). CONCLUSIONS: These findings suggest that knowledge of HPV is associated with shorter time to complete the 3-dose HPV vaccine series. Educational campaigns at time of vaccination may be important to improve vaccine adherence.
OBJECTIVE: To examine the association of knowledge about human papillomavirus (HPV) on the time to completion of the 3-dose quadrivalent vaccine series in an inner-city population of adolescent female subjects at high risk for infection. STUDY DESIGN: We prospectively followed 139 female subjects aged 14-20 years enrolled in a vaccine surveillance study in New York City during a period of at least 24 months. Participants were given a 30-item true or false survey on HPV at enrollment and ranked according to the number of correct responses. Multivariate Cox regression was used to examine the association between level of knowledge about HPV and time to completion (in days) of vaccine dose 1-3, dose 1-2, and dose 2-3. RESULTS: Overall time to completion of the 3-dose vaccine ranged from 158 days to 1114 days. Participants in the high knowledge group (top quartile) were significantly more likely to complete the 3-dose series earlier (hazard ratio 1.69, 95% CI 1.03-2.77; P = .04), in particular doses 2-3 (hazard ratio 1.71, 95% CI 1.02-2.89; P = .04), than those with low-to-moderate knowledge (bottom 3 quartiles). CONCLUSIONS: These findings suggest that knowledge of HPV is associated with shorter time to complete the 3-dose HPV vaccine series. Educational campaigns at time of vaccination may be important to improve vaccine adherence.
Authors: Debra K Braun-Courville; Nicolas F Schlecht; Robert D Burk; Howard D Strickler; Mary Rojas; Elizabeth Lorde-Rollins; Anne Nucci-Sack; Dominic Hollman; L Oriana Linares; Angela Diaz Journal: J Pediatr Adolesc Gynecol Date: 2013-12-12 Impact factor: 1.814
Authors: Tara P L Neubrand; Carmen Radecki Breitkopf; Richard Rupp; Daniel Breitkopf; Susan L Rosenthal Journal: Clin Pediatr (Phila) Date: 2009-05-29 Impact factor: 1.168
Authors: Kathleen Conroy; Susan L Rosenthal; Gregory D Zimet; Yan Jin; David I Bernstein; Susan Glynn; Jessica A Kahn Journal: J Womens Health (Larchmt) Date: 2009-10 Impact factor: 2.681
Authors: Suzanne M Garland; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Marc Steben; Janine Bryan; Frank J Taddeo; Radha Railkar; Mark T Esser; Heather L Sings; Micki Nelson; John Boslego; Carlos Sattler; Eliav Barr; Laura A Koutsky Journal: N Engl J Med Date: 2007-05-10 Impact factor: 91.245
Authors: Li Niu; Lindsay Till Hoyt; Anthony Salandy; Anne Nucci-Sack; Viswanathan Shankar; Howard Strickler; Robert D Burk; Nicolas F Schlecht; Angela Diaz Journal: Prev Med Date: 2020-05-08 Impact factor: 4.018
Authors: Lea E Widdice; Rebecca Hoagland; S Todd Callahan; Jessica A Kahn; Christopher J Harrison; Barbara A Pahud; Sharon E Frey; Andrea A Berry; Karen L Kotloff; Kathryn M Edwards; Mark J Mulligan; Jon Sudman; Aya Nakamura; David I Bernstein Journal: Vaccine Date: 2018-02-07 Impact factor: 4.169